Cargando…
Mutations driving CLL and their evolution in progression and relapse
Which genetic alterations drive tumorigenesis and how they evolve over the course of disease and therapy are central questions in cancer biology. We identify 44 recurrently mutated genes and 11 recurrent somatic copy number variations through whole-exome sequencing of 538 chronic lymphocytic leukemi...
Autores principales: | Landau, Dan A., Tausch, Eugen, Taylor-Weiner, Amaro N, Stewart, Chip, Reiter, Johannes G., Bahlo, Jasmin, Kluth, Sandra, Bozic, Ivana, Lawrence, Mike, Böttcher, Sebastian, Carter, Scott L., Cibulskis, Kristian, Mertens, Daniel, Sougnez, Carrie, Rosenberg, Mara, Hess, Julian M., Edelmann, Jennifer, Kless, Sabrina, Kneba, Michael, Ritgen, Matthias, Fink, Anna, Fischer, Kirsten, Gabriel, Stacey, Lander, Eric, Nowak, Martin A., Döhner, Hartmut, Hallek, Michael, Neuberg, Donna, Getz, Gad, Stilgenbauer, Stephan, Wu, Catherine J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815041/ https://www.ncbi.nlm.nih.gov/pubmed/26466571 http://dx.doi.org/10.1038/nature15395 |
Ejemplares similares
-
Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab
por: Fink, A M, et al.
Publicado: (2013) -
Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)
por: Cramer, Paula, et al.
Publicado: (2020) -
P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
por: Yosifov, Deyan, et al.
Publicado: (2023) -
Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022) -
CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis
por: Schilhabel, Anke, et al.
Publicado: (2022)